immunoMALDI (iMALDI)

MRM Proteomics Inc. holds a license for patented iMALDI technology that enables rapid, robust, highly automated protein quantitation in complex samples. The iMALDI approach involves spiking protein digest from a biological sample with a stable isotope-labeled standard peptide matching the target, after which the endogenous peptides and standard peptides are co-captured on antibodies conjugated to magnetic beads.

The peptides are eluted from the antibodies on a MALDI plate by applying acidic MALDI matrix, followed by MALDI-MS analysis. The use of mass spectrometry (MS) with internal standards ensures highly precise quantitation. Furthermore, detection with MS provides added protection against interferences, since the assay does not depend exclusively on the antibody for specificity. This method is compatible with the Bruker Biotyper instrument, which has already been granted FDA approval for applications in microbiology.